Indefinite Delivery Contract HSHQDC10D00025

This federal contract IDV was awarded by the U.S. Department of Homeland Security (DHS) to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to procure the antiviral medication Relenza for DHS's antiviral stockpile. The single-award contract has a ceiling value of $26,389,800 and does not have a set-aside designation. Under this IDV, DHS has issued multiple delivery orders to Glaxosmithkline for the purchase of Relenza and the related antiviral medication Zanamivir, with orders...

This indefinite delivery contract (IDC) was awarded by the U.S. Department of Health and Human Services to GlaxoSmithKline Holdings (Americas) Inc. for the acquisition of Relenza to support a public health emergency response to a pandemic. The single-award IDC has a total ceiling value of $82,861,551.35 and a period of performance running from the award date of July 14, 2006 through the ultimate completion date of September 1, 2010. This contract was not set aside for any specific...

The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $505.3 million single-award Indefinite Delivery Contract (IDC) to Alvogen, Inc. to deliver the antiviral drug oseltamivir phosphate to the Strategic National Stockpile. This IDC, which has an ultimate completion date of February 6, 2025, allows ASPR to issue task orders to Alvogen for the procurement and distribution of this essential medical countermeasure to...

The Federal Bureau of Investigation awarded Genentech USA, Inc. a single award indefinite delivery contract with a potential value of $319,384.00 to provide antiviral medications tailored for pandemic stockpiling. No set-aside designation was applied. Three firm fixed price delivery orders have been issued against the contract to date. The first, valued at $126,984, procures antiviral medication specific to the Department of Defense stockpile with an extended expiration date, to be performed...

The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Biocryst Pharmaceuticals, Inc. for the procurement of RAPIVAB. With a potential value of $625,000, the period of performance under the BPA extends through May 14, 2021. The BPA facilitates the delivery of RAPIVAB to treat influenza. As the leading cause of vaccine-preventable death in the United States, influenza places significant burden each year on the health...

The provided information describes an Indefinite Delivery Contract (IDC) awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Roche Laboratories Inc. The IDC, with a ceiling value of $131,245,722.23, is for the acquisition of the antiviral drug Tamiflu to support a public health emergency response to a pandemic. The contract was awarded on June 29, 2006, with a period of performance through September 1, 2010. This...

This indefinite delivery contract was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The contract has a ceiling value of $10,164,262.95 and a period of performance from February 22, 2024 to February 21, 2026. The purpose of this contract is to procure oseltamivir phosphate capsules and suspension for distribution to the VA, Department of Defense...

This Federal Supply Schedule contract with the Department of Veterans Affairs is a $4.9 billion multiple-award vehicle awarded to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the provision of drugs, pharmaceuticals, and hematology-related products. The contract has an ultimate completion date of September 14, 2028. Under this Federal Supply Schedule, Genentech has been awarded several delivery orders by the Department of Health and Human Services' Office of...

This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Genentech Inc. on September 27, 2018. The contract has a ceiling value of $628,598,331.30 and a period of performance through December 31, 2028. The purpose of this IDC is to fund Genentech's activities related to the development and procurement of baloxavir marboxil, an antiviral drug, under a base period task order. The contract was...

The Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Chemocentryx, Inc. for the delivery of TAVNEOS. With a potential value of $515,865, the BPA has a period of performance through October 3, 2022. TAVNEOS is a prescription medication used to treat adult patients with anti-neutrophil cytoplasmic autoantibody associated vasculitis. As the funding agency, the VA National Acquisition Center leverages BPAs to establish master...